TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16038172
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group C
Study: 16038172
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment for GERD in subgroup A1
Study: 16038172
Drug: No outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: No outpatient treatment for GERD in subgroup A2
Study: 12185449
Drug: N-acetyl-Ser-Asp-Lys-Pro (AcSDKP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-Ser-Asp-Lys-Pro (AcSDKP; 1.12 micro g kg(‐1) x min(‐1))
Study: 8684871
Drug: Brand and
Normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand and generic formulations of cephalexin and erythromycin‐sulfisoxazole
Study: 8684871
Drug: Generic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic antibiotic suspensions
Study: 27414973
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (PhC)
Study: 18060746
Drug: Ciprofloxacin 250mg
Normalized name: Ciprofloxacin 250mg/5mL Oral suspension
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin 250mg twice a day for 3 days
Study: 16171664
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral rofecoxib preoperatively with IV placebo injection
Study: 16171664
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg IV ketorolac preoperatively with placebo
Study: 11322256
Drug: Didanosine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (500 mg daily or 750 mg daily depending on weight)
Study: 11322256
Drug: Zidovudine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (600 mg daily)
Study: 11322256
Drug: Didanosine (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (low-dose)
Study: 11322256
Drug: Didanosine (high-dose)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (high-dose)
Study: 1908745
Drug: Intramuscular Ig
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Ig 25 mg/kg/wk
Study: 1908745
Drug: Intramuscular Ig
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Ig 50 mg/kg/wk
Study: 24513025
Drug: Citalopram (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (30 mg)
Study: 31842388
Drug: Stevia (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stevia (1 g)
Study: 31842388
Drug: Sugar (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar (60 g)
Study: 19700435
Drug: Pre-treatment colonic
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment colonic mucosal gene expression profiles
Study: 17005066
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST) combined with 5 mg of donepezil per day for one year.
Study: 17005066
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of donepezil per day (control group).
Study: 8557061
Drug: Cholestyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (4 g with a liquid meal)
Study: 8557061
Drug: Cholestyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (4 g every 2 days for 1 month)
Study: 8557061
Drug: Liquid meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid meal (two egg yolks plus water 200 mL, 50 kJ)
Study: 1973768
Drug: L-thyroxine (T4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (T4, 2.5 micrograms/kg body weight daily)
Study: 1973768
Drug: L-thyroxine (T4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (T4, 2.5 micrograms/kg body weight daily) + carbimazole (CBZ, 40 mg daily)
Study: 19114187
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood component therapy
Study: 10675166
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (control group)
Study: 8814201
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (35 mg 20:5(n‐3) + 22:6(n‐3)/(kg body weight.d))
Study: 8814201
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (35 mg 18:3(n‐3)/(kg body weight.d))
Study: 8814201
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (35 mg 18:1/(kg body weight.d))
Study: 8814201
Drug: All oil
Normalized name: TALL OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: All oil treatments
Study: 6368906
Drug: Granulocyte transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte transfusions plus antibiotic therapy (IFCL & CFCL group)
Study: 6368906
Drug: Granulocyte transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte transfusions plus antibiotic therapy (FL group)
Study: 6368906
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy alone (control group)
Study: 6368906
Drug: Granulocyte transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte transfusions plus antibiotic therapy (all transfused patients)
Study: 31509182
Drug: 200/50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/50 mg dispersible levodopa/benserazide
Study: 26052813
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of daily topical antioxidant hydrogel plus excimer light (Group A)
Study: 24774442
Drug: Intravaginal prasterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal prasterone (DHEA) 0, 3.25 mg, 6.5 mg or 13 mg daily for 12 weeks
Study: 22815298
Drug: CLP (closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLP (closed-loop control plus 30-μg premeal injections of pramlintide)
Study: 20051276
Drug: AMA1-C1 vaccine
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-C1 vaccine (5 microg)
Study: 20051276
Drug: AMA1-C1 vaccine
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-C1 vaccine (20 microg)
Study: 20051276
Drug: AMA1-C1 vaccine
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-C1 vaccine (80 microg)
Study: 20051276
Drug: AMA1-C1 vaccine
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-C1 vaccine (5 microg and 20 microg)
Study: 7622915
Drug: Fluconazole 1200
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 1200 mg/day
Study: 7622915
Drug: Fluconazole 1600
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 1600 mg/day
Study: 7622915
Drug: Fluconazole 2000
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 2000 mg/day
Study: 2142394
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg medroxyprogesterone acetate (MPA) twice weekly for 3 months
Study: 423112
Drug: Personal interview
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal interview and capsule count
Study: 25773309
Drug: Partial weight
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial weight bearing beginning the same day of conservative treatment (Group 1)
Study: 11543734
Drug: Fluvoxamine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 300 mg
Study: 16441740
Drug: 2% minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minocycline gel
Study: 30079613
Drug: Emergency endodontic
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency endodontic treatment
Study: 20847017
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucosamine and chondroitin
Study: 12903700
Drug: Heparin flushes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin flushes (10 U/mL, 1 mL)
Study: 12903700
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline flushes (1 mL)
Study: 2015168
Drug: Pinacidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (25 mg, sustained release formulation)
Study: 6794086
Drug: Lysine-8-vasopressin (LVP)
Normalized name: Vasopressin, 8-L-lysine
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lysine-8-vasopressin (LVP) at a dosage starting from 22.5 IU/day to 67.5 IU/day over 3 weeks
Study: 30639574
Drug: Preventive intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive intramuscular use of 5 mg phenylephrine
Study: 30639574
Drug: Preventive intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive intravenous use of 100 μg phenylephrine
Study: 28490464
Drug: β-adrenergic antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: β-adrenergic antagonist (propranolol) and COX-2 inhibitor (etodolac) for 11 days, starting 5 days before surgery
Study: 19951210
Drug: Balance exercises
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance exercises (11 exercises, twice per week)
Study: 9451748
Drug: rIL-2 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIL-2 with chemotherapy (5-fluorouracil and leucovorin)
Study: 15374271
Drug: Ipriflavone (IP)
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (IP) 3 x 200 mg/day
Study: 2828820
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg/d for 5 days)
Study: 25646357
Drug: 2-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF)
Study: 18186564
Drug: Pegylated-interferon alpha-2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated-interferon alpha-2a (135 microg weekly for 48 weeks)
Study: 17213004
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (S‐amlodipine 5 mg p.o.)
Study: 17213004
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (racemate 10 mg p.o.)
Study: 8643897
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy (BEAM) with autologous stem cell rescue
Study: 1448312
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 6 months
Study: 1448312
Drug: 2 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 2 months
Study: 1448312
Drug: 2 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 2 months (specific subgroup)
Study: 3882143
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg, three times daily
Study: 3882143
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg (single dose)
Study: 19136303
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate 15 mg weekly for 40 weeks (7.5 mg weekly for 4 weeks, then 10 mg weekly for 4 weeks, then 15 mg weekly for 32 weeks)
Study: 9741509
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/day + colestipol 20 g/day
Study: 8000839
Drug: iomeprol-300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol-300 (300 mg I ml-1)
Study: 8000839
Drug: iopromide-300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide-300 (300 mg I ml-1)
Study: 20418538
Drug: Methadone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.2 mg/kg) before surgical incision
Study: 20418538
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion (0.25 μg/kg/h after a load of 0.75 μg/kg)
Study: 16480794
Drug: TdPa formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: TdPa formulations with inactivated poliomyelitis vaccine (IPV)
Study: 16480794
Drug: TdPa formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: TdPa formulations without inactivated poliomyelitis vaccine (IPV)
Study: 16480794
Drug: Mouse booster
Normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouse booster model with whole cell pertussis vaccine priming
Study: 12562658
Drug: Granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2 mg p.o. on day 1, followed by dexamethasone 4 mg p.o. od for 5 days
Study: 12562658
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg p.o. tds combined with dexamethasone 4 mg p.o. od for 5 days
Study: 9302466
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy at 2 atmospheres absolute pressure
Study: 9302466
Drug: Air treatment
Normalized name: GLYCERIN 3.88 mg in 1 mL TOPICAL SHAMPOO [HAIR TREATMENT PREMIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air treatment at 1.1 atmosphere absolute pressure
Study: 3098270
Drug: Ro 15-1788
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-1788 (0.5 mg intravenous bolus)
Study: 26481332
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (re-esterified triacylglycerol fish oil capsule)
Study: 25304298
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and radical hypofractionated radiotherapy (cisplatinum and vinorelbine with 55Gy in 20 fractions over four weeks)
Study: 25304298
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy and radical hypofractionated radiotherapy (cisplatinum and vinorelbine with 55Gy in 20 fractions over four weeks)
Study: 25304298
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and radical hypofractionated radiotherapy
Study: 12912859
Drug: IFN‐beta‐1a (22
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐beta‐1a (22 micro g three times a week subcutaneously, increased to 44 micro g and then to 88 micro g if no response, maximum duration of treatment 8 weeks)
Study: 7000128
Drug: Fenoterol 2
Normalized name: fenoterol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 2 mg administered by intermittent positive pressure breathing (IPPB) in 40% oxygen
Study: 7000128
Drug: Terbutaline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 10 mg administered by intermittent positive pressure breathing (IPPB) in 40% oxygen
Study: 24065443
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg LD alone
Study: 24065443
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg plus prasugrel 60 mg
Study: 24065443
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg plus prasugrel 30 mg
Study: 21220618
Drug: Weekly doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly doxorubicin and daily oral cyclophosphamide with granulocyte colony-stimulating factor support for 15 weeks (continuous arm)
Study: 21220618
Drug: Standard doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doxorubicin and cyclophosphamide administered for five cycles (standard arm)
Study: 21220618
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel for 12 weeks before surgery (both arms)
Study: 31732233
Drug: Monthly blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly blood sampling
Study: 20066450
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 40 mg every other week
Study: 27147222
Drug: MRgFUS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRgFUS treatment
Study: 24351233
Drug: Pregabalin 450-600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 450-600 mg/d
Study: 24351233
Drug: Pregabalin 150-300
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150-300 mg/d
Study: 24351233
Drug: Lorazepam 3-4
Normalized name: lorazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 3-4 mg/d
Study: 24351233
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Pregabalin and Lorazepam)
Study: 22664339
Drug: Topical eprinomectin
Normalized name: eprinomectin Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eprinomectin (≥ 0.05 mg/kg) every 28 days for eight treatments during lactation
Study: 16135464
Drug: Schedule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A (pemetrexed 500 mg/m2 followed by gemcitabine 1,250 mg/m2 on day 1 and gemcitabine on day 8)
Study: 10099065
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebivolol once daily
Study: 10099065
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine retard twice daily
Study: 28164346
Drug: Palmithoylethanolamide/polydatin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmithoylethanolamide/polydatin 200 mg/20 mg
Study: 26994230
Drug: extrafascial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: extrafascial injection
Study: 26994230
Drug: conventional intrafascial
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional intrafascial injection
Study: 24608069
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg film-coated tablet (fasted)
Study: 24608069
Drug: four 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: four 100 mg EC tablets (fasted)
Study: 24608069
Drug: one 400
Normalized name: dipyrone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 400 mg GFS dose (fasted)
Study: 24608069
Drug: four 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: four 100 mg EC tablets (after a high-fat meal)
Study: 22568162
Drug: VCT/VCUG combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCT/VCUG combination group
Study: 17177199
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean dose 182 mg/day)
Study: 14667422
Drug: Node-link mapping
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Node-link mapping group treatment (n=4)
Study: 14667422
Drug: Non-mapping group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-mapping group treatment (n=4)
Study: 14667422
Drug: Node-link mapping
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Node-link mapping group treatment (n=9 in Experiment 2)
Study: 11724078
Drug: PAS granules
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS granules (6 g) with high-fat food
Study: 11724078
Drug: PAS granules
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS granules (6 g) with orange juice
Study: 11724078
Drug: PAS granules
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS granules (6 g) with food
Study: 11724078
Drug: PAS granules
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS granules (6 g) with antacids
Study: 9190323
Drug: Tramadol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (up to 600mg daily, mean daily dose 250 to 290mg)
Study: 9190323
Drug: Clomipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (up to 100mg daily, mean daily dose 59.1 to 63.6mg) with or without levomepromazine (100mg)
Study: 7955956
Drug: Aminoglutethimide (AG;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide (AG; 500 mg daily plus hydrocortisone 40 mg daily)
Study: 7955956
Drug: Medroxyprogesterone (MPA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone (MPA; 1,000 mg daily per os)
Study: 29497150
Drug: IND (indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND (indapamide 1.25-2.5 mg daily)
Study: 29497150
Drug: IND/KCl (indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/KCl (indapamide 1.25-2.5 mg daily plus potassium chloride 40 mmol daily)
Study: 23254962
Drug: Inductive chemotherapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inductive chemotherapy plus radiation therapy (IC + RT) with 2-3 cycles of cisplatin (80 mg/m²) and fluorouracil (500 mg/m²), followed by radiotherapy.
Study: 23254962
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with weekly cisplatin (40 mg/m²) for 6-7 cycles during radiotherapy.
Study: 23254962
Drug: Inductive chemotherapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inductive chemotherapy plus concurrent chemoradiotherapy (IC + CCRT) with similar chemotherapy regimen as IC + RT followed by CCRT regimen.
Study: 23254962
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (RT).
Study: 19854590
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg IV single dose)